PE20130317A1 - Derivados de amino-tropano - Google Patents

Derivados de amino-tropano

Info

Publication number
PE20130317A1
PE20130317A1 PE2012002444A PE2012002444A PE20130317A1 PE 20130317 A1 PE20130317 A1 PE 20130317A1 PE 2012002444 A PE2012002444 A PE 2012002444A PE 2012002444 A PE2012002444 A PE 2012002444A PE 20130317 A1 PE20130317 A1 PE 20130317A1
Authority
PE
Peru
Prior art keywords
methyl
aza
benzamide
bicycle
trifluoromethyl
Prior art date
Application number
PE2012002444A
Other languages
English (en)
Inventor
Sabine Kolczewski
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20130317A1 publication Critical patent/PE20130317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE AMINO-TROPANO DE FORMULA (I) DONDE R1, R2 Y R3 SON CADA UNO H, ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALCOXI INFERIOR, CICLOALQUILO O S-ALQUILO INFERIOR. SON COMPUESTOS PREFERIDOS: 2-METOXI-N-((1S,2S,5R)-8-METIL-2-FENIL-8-AZA-BICICLO[3.2.1]OCT-2-IL)-6-METILSULFANIL-4-TRIFLUOROMETIL-BENZAMIDA; 2-CICLOPROPIL-N-((1RS,2RS,5SR)-8-METIL-2-FENIL-8-AZA-BICICLO[3.2.1]OCT-2-IL)-4-TRIFLUOROMETIL-BENZAMIDA; 2-METOXI-6-METIL-N-((1RS,2RS,5SR)-8-METIL-2-FENIL-8-AZA-BICICLO[3.2.1]OCT-2-IL)-4-TRIFLUOROMETIL-BENZAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE GLICINA 1 (GlyT-1) SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, TRASTORNOS DE DEMENCIA, ENFERMEDAD DE ALZHEIMER
PE2012002444A 2010-06-22 2011-06-17 Derivados de amino-tropano PE20130317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10166757 2010-06-22

Publications (1)

Publication Number Publication Date
PE20130317A1 true PE20130317A1 (es) 2013-03-11

Family

ID=44310862

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002444A PE20130317A1 (es) 2010-06-22 2011-06-17 Derivados de amino-tropano

Country Status (24)

Country Link
US (1) US8153653B2 (es)
EP (1) EP2585456B1 (es)
JP (1) JP5546684B2 (es)
KR (1) KR101445016B1 (es)
CN (1) CN102947297B (es)
AR (1) AR081961A1 (es)
AU (1) AU2011269145A1 (es)
BR (1) BR112012032576A2 (es)
CA (1) CA2801458C (es)
CL (1) CL2012003552A1 (es)
CO (1) CO6630160A2 (es)
CR (1) CR20120614A (es)
EA (1) EA201291374A1 (es)
EC (1) ECSP12012347A (es)
ES (1) ES2550831T3 (es)
HK (1) HK1179606A1 (es)
IL (1) IL222998A0 (es)
MA (1) MA34251B1 (es)
MX (1) MX2012013820A (es)
PE (1) PE20130317A1 (es)
SG (1) SG186329A1 (es)
TW (1) TWI417097B (es)
WO (1) WO2011161006A1 (es)
ZA (1) ZA201209248B (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04751B1 (et) * 1996-02-22 2006-12-15 Neurosearch A/S Tropaani derivaadid, nende valmistamine ja kasutamine
US5834484A (en) * 1997-03-12 1998-11-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cocaine analogs
JP4563386B2 (ja) * 2003-09-09 2010-10-13 エフ．ホフマン−ラ ロシュ アーゲー 精神病の処置のためのグリシン取り込み阻害剤としての１−（２−アミノ−ベンゾール）−ピペラジン誘導体
FR2861076B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
US7572792B2 (en) * 2004-04-29 2009-08-11 Merck & Co., Inc. Azetidine glycine transporter inhibitors
FR2873693B1 (fr) * 2004-07-29 2006-09-15 Sanofi Synthelabo Derives d'amino-tropane, leur preparation et leur application en therapeutique
GB0428231D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
MX2007008190A (es) * 2005-01-06 2007-08-07 Hoffmann La Roche Fenil metanonas sustituidas con sulfanilo como inhibidores del transportador de glicina 1 (glyt-1) para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
EP2121622A1 (en) * 2007-02-01 2009-11-25 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2010020548A1 (en) * 2008-08-20 2010-02-25 F. Hoffmann-La Roche Ag Glyt1 receptor antagonists

Also Published As

Publication number Publication date
MX2012013820A (es) 2013-01-28
CO6630160A2 (es) 2013-03-01
JP5546684B2 (ja) 2014-07-09
EP2585456B1 (en) 2015-09-16
CL2012003552A1 (es) 2013-04-12
BR112012032576A2 (pt) 2016-11-22
CN102947297A (zh) 2013-02-27
MA34251B1 (fr) 2013-05-02
ECSP12012347A (es) 2013-01-31
EP2585456A1 (en) 2013-05-01
US8153653B2 (en) 2012-04-10
CA2801458C (en) 2018-10-30
CN102947297B (zh) 2015-12-16
ES2550831T3 (es) 2015-11-12
US20110312993A1 (en) 2011-12-22
AR081961A1 (es) 2012-10-31
KR101445016B1 (ko) 2014-09-26
TW201206438A (en) 2012-02-16
EA201291374A1 (ru) 2013-06-28
JP2013529607A (ja) 2013-07-22
SG186329A1 (en) 2013-01-30
IL222998A0 (en) 2013-02-03
AU2011269145A1 (en) 2012-11-08
KR20130029414A (ko) 2013-03-22
TWI417097B (zh) 2013-12-01
WO2011161006A1 (en) 2011-12-29
CR20120614A (es) 2013-01-11
HK1179606A1 (zh) 2013-10-04
ZA201209248B (en) 2013-08-28
CA2801458A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CL2010001159A1 (es) Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.
MX2014002113A (es) Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
IN2014DN03206A (es)
UY29301A1 (es) Derivados amida
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
PE20170464A1 (es) Terapia de combinacion de alzheimer usando un anticuerpo monoclonal abeta anti-n3pglu mas un inhibidor de bace
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.
PE20170427A1 (es) Peptidos como agonistas de la oxitocina
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EP2602255A4 (en) FUSED HETEROCYCLIC CYCLE COMPOUND

Legal Events

Date Code Title Description
FA Abandonment or withdrawal